Vildagliptin

vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by increasing the amount of two incretin hormones found in the body, called glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones are normally produced naturally by the body in response to food intake. Their function is to help control blood sugar (glucose) levels. It is used to treat type 2 or non-insulin dependent diabetes (NIDDM) in combination with a sulphonylurea (50 mg once daily), metformin or a glitazone (50 mg twice daily).

Brands
VIGLIP-M VIGLIP-M GLAVIL VILDOS VILDOMET VILDOMET GALVUSMET GALVUSMET METLIPTIN METLIPTIN
Adult Dose
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Neonatal
Paedriatic
Characteristics
It belongs to DPP-4 inhibitor pharmacological group on the basis of mechanism of action. The Molecular Weight of vildagliptin is 303.40.
Contraindications
vildagliptin is contraindicated in conditions like Hypersensitivity to the drug.
Effects
vildagliptin produces potentially life-threatening effects which include Angioedema. which are responsible for the discontinuation of vildagliptin therapy.The signs and symptoms that are produced after the acute overdosage of vildagliptin include Muscle aches, Fever, Swelling of feet and lower legs, Mild paresthesia.The symptomatic adverse reactions produced by vildagliptin are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fatigue, Nausea, Asthenia, Hypoglycemia.
Indications
vildagliptin is primarily indicated in conditions like Type II diabetes mellitus.
Interactions
No data regarding the interactions of vildagliptin was found.
Interfrence
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
tablet Store Below 30°C. Protect from Moisture.
Warnings
Do not use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. not recommended in ESRD on haemodialysis patients. Do not use in patients with hepatic impairment, including patients with pre-treatment ALT or AST > 3x ULN. Liver function should be monitored during treatment with vildagliptin at three-month intervals during the first year and periodically thereafter. Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue it. Following withdrawal of treatment with vildagliptin and LFT normalisation, treatment with vildagliptin should not be reinitiated. Monitoring for skin disorders, such as blistering or ulceration, is recommended while keeping with routine care of the diabetic patient.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.